Patent classifications
C12N9/0022
CYCLOPROPYLAMINES AS LSD1 INHIBITORS
The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
BACTERIA FOR THE TREATMENT OF DISORDERS
Modified probiotics, pharmaceutical compositions thereof, and methods of modulating and treating disorders are disclosed.
A FIRE-PROTECTING INSULATION PRODUCT AND USE OF SUCH PRODUCT
A fire-protecting insulation product has air-laid mineral wool fibres and a binder. The binder is the result of curing a binder composition comprising at least one hydrocolloid. The product further comprises a particulate endothermic material.
Compositions and methods for making (S)-norcoclaurine and (S)-norlaudanosoline, and synthesis intermediates thereof
Methods that may be used for the manufacture of the chemical compound (S)-norcoclaurine, (S)-norlaudanosoline, and (S)-norcoclaurine or (S)-norlaudanosoline synthesis intermediates are provided. (S)-Norcoclaurine, (S)-norlaudanosoline, and (S)-norcoclaurine or (S)-norlaudanosoline synthesis intermediates are useful as precursor products in the manufacture of certain medicinal agents.
GENOME EDITING METHODS FOR PRODUCING LOW-NICOTINE TOBACCO PRODUCTS
The present technology provides targeted genome engineering (also known as genome editing) techniques to modify nicotine biosynthesis. In particular, the present technology relates to the use of genome editing methods to generate mutations resulting in an out-of-frame start codon upstream of the open reading frames (ORFs) of genes of interest, such as nicotine biosynthesis genes, to genetically engineer protein translation levels and modulate nicotine production in plants for producing plants and plant cells having reduced nicotine content.
TAL EFFECTOR-MEDIATED DNA MODIFICATION
Materials and methods related to gene targeting (e.g., gene targeting with transcription activator-like effector nucleases; TALENS) are provided.
Quantification method of ethanolamine phosphate, oxidoreductase for quantification, composition for quantification, kit for quantification and sensor for quantification
There is provided a novel quantification method for quantifying a concentration of EAP, which is a biomarker of depression, an enzyme for quantitation, a composition for quantitation, a kit for quantitation or a sensor for quantitation. There is provided a quantification method of ethanolamine phosphate by adding oxidoreductase to a sample containing ethanolamine phosphate. A mediator may be reduced by adding the oxidoreductase, and the reduced mediator may be reacted with a reagent to determine a concentration of ethanolamine phosphate. In addition, hydrogen peroxide produced by adding the oxidase as the oxidoreductase may be reacted with a reagent to determine a concentration of the ethanolamine phosphate.
A METHOD OF BONDING TOGETHER SURFACES OF TWO OR MORE ELEMENTS AND A PRODUCT MADE BY SAID METHOD
A method of bonding together surfaces of two or more elements. The method includes the steps of providing two or more elements, applying an adhesive to one or more of the surfaces to be bonded together before, during or after contacting the surfaces to be bonded together with each other, and curing the adhesive, wherein the adhesive comprises at least one hydrocolloid.
ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES
The present invention provides engineered phenylalanine ammonia lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia lyase (PAL) polypeptides. Methods for producing PAL enzymes are also provided. In some embodiments, the engineered PAL polypeptides are optimized to provide enhanced catalytic activities that are useful under industrial process conditions for the production of pharmaceutical compounds.
Eggshell membrane solubilization method using enzymes
The present invention addresses the problem of providing an eggshell membrane solubilization method that is capable of solving the problems associated with carrying out treatment using acids and alkalis, or problems associated with the processing methods of the conventional art that use proteases; in other words, an eggshell membrane solubilization method that is capable of solving at least one of the following problems: (1) the need for pretreatment such as pulverization, sonication or boiling; (2) the need for prolonged treatment; and (3) a low decomposition rate (approximately 20%). Eggshell membranes are efficiently solubilized by using a protease in combination with a reducing agent.